Athens
,
Greece
24 - 27 May 2026
European Atherosclerosis Society (EAS 2026)
Presentation schedule and materials
Monday, 25 May 2026
13:30
- 13:37
EEST
289
POSTER
A quantitative model to estimate free IL-6 levels among participants treated
with the IL-6 ligand inhibitor ziltivekimab: implications for the ZEUS, HERMES,
and ARTEMIS trials
with the IL-6 ligand inhibitor ziltivekimab: implications for the ZEUS, HERMES,
and ARTEMIS trials
Bibi Toft Hellinghus1; Katherine Tuttle2; Magnus Fugger1; Ingo Hilgendorf3; Jesper Falkesgaard Højen1; Peter Libby4; Giovanna Liuzzo5; Christian M Matter6; Patrick Nolain1; Paul M Ridker7
MATERIALS AVAILABLE
Tuesday, 26 May 2026
11:40
- 11:50
EEST
1655
ORAL PRESENTATION
Prevalence of high inflammatory risk in atherosclerotic cardiovascular disease with and without chronic kidney disease: Findings from POSEIDON – a global cross-sectional prevalence study
Ann Marie Navar1; Ling Bai2; Jesper Falkesgaard Højen3; Fabrice Ivanes4; Søren Lund Kristensen3; Carolyn S P Lam5; Ulf Landmesser6; Kelvin Lee7; Giovanna Liuzzo8; Lilia Nigro Maia9; Jimmi Mathisen3; Adam J Nelson10; Amritanshu Shekhar Pandey11; Pablo E Pergola12; Hongye Ren3; Kenichi Tsujita13; Nikolaus Marx14
MATERIALS AVAILABLE
Keywords